Pfizer, Inc. (NYSE:PFE)‘s stock had its “hold” rating restated by research analysts at Jefferies Group LLC in a research note issued to investors on Friday. They presently have a $35.00 price objective on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target points to a potential upside of 6.22% from the company’s previous close.

PFE has been the subject of a number of other reports. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets raised Pfizer from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $33.00 to $37.00 in a research report on Wednesday, August 2nd. UBS AG reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a research report on Monday, July 31st. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Finally, Barclays PLC reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a research report on Wednesday, May 3rd. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $37.61.

Shares of Pfizer (PFE) traded down 0.622% on Friday, reaching $32.745. The company’s stock had a trading volume of 4,777,452 shares. The company’s 50 day moving average is $33.33 and its 200-day moving average is $33.37. The firm has a market cap of $194.75 billion, a price-to-earnings ratio of 23.954 and a beta of 1.00. Pfizer has a 1-year low of $29.83 and a 1-year high of $35.38.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the prior year, the firm posted $0.64 earnings per share. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. Equities research analysts expect that Pfizer will post $2.56 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Pfizer, Inc. (PFE) Given “Hold” Rating at Jefferies Group LLC” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/08/18/pfizer-inc-pfe-given-hold-rating-at-jefferies-group-llc.html.

In other news, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the transaction, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Pfizer by 2.3% in the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after buying an additional 9,239,499 shares during the last quarter. Norges Bank acquired a new position in shares of Pfizer during the fourth quarter valued at about $1,896,890,000. Franklin Resources Inc. raised its position in shares of Pfizer by 0.9% in the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after buying an additional 389,629 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Pfizer by 4.8% in the second quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after buying an additional 2,028,313 shares during the last quarter. Finally, Fisher Asset Management LLC raised its position in shares of Pfizer by 3.9% in the second quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock valued at $1,143,248,000 after buying an additional 1,275,832 shares during the last quarter. Institutional investors own 69.94% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.